Uncategorized

Orexin Antagonists for Insomnia: Belsomra, Dayvigo, Quviviq

Orexin antagonists for insomnia, also called dual orexin receptor antagonists or DORAs, work by blocking orexin, a brain signal that keeps you awake. Three are FDA-approved: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq). Meta-analyses show they beat placebo on most sleep measures, with downsides including next-day sleepiness, abnormal dreams, fatigue, and dry mouth. Sleep paralysis

Orexin Antagonists for Insomnia: Belsomra, Dayvigo, Quviviq Read More »

Sleep Supplement Interactions: Check Before You Stack

“Natural” does not mean “interaction-free.” Common sleep supplements can change how prescription drugs work, or stack sedation on top of them. St. John’s wort carries the longest interaction list, because it speeds up how your liver breaks down many medicines. Melatonin can raise bleeding risk with blood thinners and rise sharply with the antidepressant fluvoxamine.

Sleep Supplement Interactions: Check Before You Stack Read More »

Central Sleep Apnea: Causes, Symptoms & Treatment Options

Central sleep apnea is a sleep breathing disorder in which the brain temporarily fails to signal the breathing muscles, so you stop breathing during sleep without an airway blockage. Common causes include heart failure, stroke, opioid use, high altitude, and CPAP treatment for obstructive apnea. Symptoms overlap with obstructive apnea, including waking short of breath,

Central Sleep Apnea: Causes, Symptoms & Treatment Options Read More »

Gabapentin for Sleep: Does It Work, What Are the Risks, and What Are the Alternatives?

Gabapentin for sleep is an off-label use of a seizure and nerve-pain medicine, and good evidence for treating insomnia on its own is limited. It is FDA-approved for seizures and postherpetic neuralgia, and it also has guideline support for restless legs syndrome, but it is not approved for insomnia. In 2019 the FDA warned of

Gabapentin for Sleep: Does It Work, What Are the Risks, and What Are the Alternatives? Read More »